TY - JOUR T1 - Atlas of epistasis JF - medRxiv DO - 10.1101/2021.03.17.21253794 SP - 2021.03.17.21253794 AU - Clément Chatelain AU - Samuel Lessard AU - Vincent Thuillier AU - Cedric Carliez AU - Deepak Rajpal AU - Franck Augé Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/24/2021.03.17.21253794.abstract N2 - We performed a genome-wide epistasis search across 502 phenotypes in case control matched cohorts from the UK Biobank. We identified 152,519 genome wide significant interactions in 68 distinct phenotypes, and 3,398 interactions in 19 phenotypes were successfully replicated in independent cohorts from the Finngen consortium. Most interactions (79%) involved variants that did not present significant marginal association and might explain part of the missing heritability for these diseases. In 10 phenotypes we show the presence of epistasis between common variants with intermediate to large effect size (OR > 2) supporting the hypothesis that common diseases are modulated by common variants. Most of the variants in interactions (82%) were more than 1Mb apart and cis-epistasis was hardly found outside the HLA region. Functional annotation of the variants suggests that most mechanisms behind epistasis occurs at the supra pathway level and that intra-gene or intra-pathway epistasis is rare. Surprisingly we find a significant biais toward antagonistic epistasis, representing 60% to 95% of interactions. In type 1 diabetes, hypothyroidism, disorders of mineral absorption, rheumatoid arthritis, asthma, and multiple sclerosis more than 50% of interactions were completely compensating the effect of the marginally associated variant. In psoriasis we identified an interaction between a stop gain variant in CCHCR1 with two missense variants in MUC22 and HSPA1L leading to a 3 fold increase of the effect of CCHCR1 variant on disease risk. Our study shows that there is still much to discover in epistasis and we provide the full summary statistics results to researchers interested in studying epistasis.Competing Interest StatementAll authors are employees of Sanofi.Funding StatementThe work is fully supported by Sanofi.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used for this analysis comes from the UK Biobank and FinnGen Consortia. All analyses were performed in compliance with consortia data use agreements and in secure computing environments. Prior to submission, the submitted manuscript was reviewed by UK Biobank and FinnGen to further ensure ethical compliance and written confirmation of approval for publication has been obtained from both UK Biobank and FinnGen.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll results summary statistics (p<1e-3) will be freely available. ER -